Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
05/1995
05/26/1995CA2176507A1 Endothelin-converting enzyme
05/26/1995CA2176498A1 Synthetic oligomers having phosphonate internucleosidyl linkages of undefined chirality mixed with non-phosphonate internucleosidyl linkages
05/26/1995CA2176372A1 Chirally enriched synthetic phosphonate oligomers
05/26/1995CA2176259A1 Chimeric oligonucleoside compounds
05/26/1995CA2176256A1 Synthetic oligomers having chirally pure phosphonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages
05/26/1995CA2176014A1 Transcriptional regulatory sequence of carcinoembryonic antigen for expression targeting
05/26/1995CA2174860A1 Myocardial grafts and cellular compositions useful for same
05/26/1995CA2153482A1 Delivery of gene products via mesangial cells
05/24/1995EP0654268A1 A method to reverse the phenotype of transformed cells by the transcription factor IRF-1
05/24/1995EP0653943A1 Targeting somatic gene therapy to joints
05/24/1995EP0653942A1 Morphogen-induced nerve regeneration and repair
05/24/1995EP0604560A4 Human cyclin e.
05/24/1995EP0520029B1 Methods and compositions for the treatment of malignancies in which a protein kinase is associated
05/23/1995US5417978 Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
05/18/1995WO1995013391A1 Method of treatment using, process of preparing, and composition comprising a recombinant hsv-1
05/18/1995WO1995013379A1 Alteration of sequence of a target molecule
05/18/1995WO1995013377A1 Episomal expression vector for human gene therapy
05/18/1995WO1995013376A1 Gene therapy vector for the treatment of low or defective red blood cell production
05/18/1995WO1995013370A1 Haemophilus transferrin receptor genes
05/18/1995WO1995013365A1 Generation of high titers of recombinant aav vectors
05/18/1995WO1995013364A1 In situ modification and manipulation of stem cells of the central nervous system
05/18/1995WO1995013363A1 Hematopoietic stem cells from swine cord blood and uses thereof
05/18/1995WO1995013081A1 Lymphotropic agents and vectors
05/18/1995WO1995012982A1 Compositions and methods for producing and using homogeneous neuronal cell transplants
05/18/1995WO1995012979A1 Compositions and methods for transduction of cells
05/18/1995WO1995011962A3 Method of controlled genetic transformation of an animal mammary gland and a device for introducing genetic material into the mammary duct of an animal mammary gland
05/18/1995DE4326821A1 New cancer vaccine based on autologous, transfected tumour cells
05/18/1995CA2183551A1 Gene therapy vector for the treatment of low or defective red blood cell production
05/18/1995CA2176284A1 Method of treatment using, process of preparing, and composition comprising a recombinant hsv-1
05/18/1995CA2176216A1 Compositions and methods for producing and using homogeneous neuronal cell transplants
05/17/1995EP0652972A1 Pseudo-half-knot rna formation by hybridization of antisense oligonucleotides to target rna's secondary structure
05/17/1995EP0652968A1 Defective adenoviruses and corresponding complementation lines
05/17/1995EP0652967A1 Self-assembling replication defective hybrid virus particles
05/17/1995EP0652953A1 Morphogenic protein soluble complex and composition thereof
05/17/1995EP0652952A1 Peptides inhibiting ras protein activity, preparation and use thereof
05/17/1995EP0652948A1 Development of a vector to target gene expression to the epidermis of transgenic animals
05/17/1995EP0652890A1 Oligonucleotide alkylphosphonothioates
05/17/1995EP0652889A1 Production of recombinant polypeptides by bovine species and transgenic methods
05/17/1995EP0652888A1 INHIBITION OF $i(CANDIDA)
05/11/1995WO1995012681A1 Methods relating to ir-95
05/11/1995WO1995012678A2 Improvements relating to cancer therapy
05/11/1995WO1995012660A2 Recombinant p53 adenovirus methods and compositions
05/11/1995WO1995012415A1 Modulation of vascular cell adhesion molecule expression through novel oligonucleotide interactions
05/11/1995WO1995012392A1 Biochemically active agents for chemical catalysis and cell receptor activation
05/11/1995WO1995012317A1 Improved postanatal and in utero fetal hematopoietic stem cell transplantation methods
05/11/1995WO1995000638A3 Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
05/11/1995CA2175922A1 Methods relating to ir-95
05/11/1995CA2175902A1 Modulation of vascular cell adhesion molecule expression through novel oligonucleotide interactions
05/11/1995CA2174244A1 Biochemically active agents for chemical catalysis and cell receptor activation
05/10/1995EP0651824A1 Transcription control element for increasing gene expression in myoblasts
05/10/1995EP0651807A1 New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents
05/10/1995EP0651798A1 Target antigens of transmission blocking antibodies for malaria parsites
05/10/1995EP0651796A1 Unstabilising viral quasi-species distributions for avoiding resistance phenomena
05/10/1995EP0651759A1 Novel 2'-o-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof
05/09/1995US5413914 Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
05/04/1995WO1995011984A2 Recombinant adenoviral vector and methods of use
05/04/1995WO1995011962A2 Method of controlled genetic transformation of an animal mammary gland and a device for introducing genetic material into the mammary duct of an animal mammary gland
05/04/1995WO1995011910A1 2'-amido and 2'-peptido modified oligonucleotides
05/04/1995WO1995011694A1 Compositions that specifically bind to colorectal cancer cells and methods of using the same
05/04/1995WO1995011687A1 Therapeutic use of cis-element decoys in vivo
05/04/1995WO1995011684A1 Antagonistic inhibitor against mesenchymal cell growth
05/04/1995WO1995011664A1 Method for preparing a viral aerosol
05/04/1995CA2174339A1 2'-amido and 2'-peptido modified oligonucleotides
05/04/1995CA2174210A1 Method of controlled genetic transformation of an animal mammary gland and a device for introducing genetic material into the mammary duct of an animal mammary gland
05/03/1995EP0650493A1 Hybrid oligonucleotide phosphorothioates
05/03/1995EP0650370A1 Methods and compositions for targeting specific tissue
05/03/1995EP0650368A1 Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity
05/03/1995CN2196119Y Gene gun
05/02/1995US5411860 Amplification of human MDM2 gene in human tumors
04/1995
04/27/1995WO1995011309A2 A novel nuclear mitotic phosphoprotein: mitosin
04/27/1995WO1995011307A1 Nucleotide vector, composition containing such vector and vaccine for immunization against hepatitis
04/27/1995WO1995011301A1 P53-mediated apoptosis
04/27/1995WO1995011253A1 A method for enhancing neurone survival and agents useful for same
04/27/1995WO1995011048A2 METHODS AND COMPOSITIONS OF A BIOARTIFICIAL KIDNEY SUITABLE FOR USE IN VIVO OR $i(EX VIVO)
04/27/1995WO1995010938A1 Oligonucleotide modulation of multidrug resistance-associated protein
04/27/1995CA2174425A1 A method for enhancing neurone survival and agents useful for same
04/27/1995CA2173978A1 A novel nuclear mitotic phosphoprotein: mitosin
04/26/1995EP0649467A1 Self-stabilized oligonucleotides as therapeutic agents
04/20/1995WO1995010630A1 Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins
04/20/1995WO1995010623A1 Selective adenoviral mediated gene transfer into vascular neointima
04/20/1995WO1995010611A1 Method of inducing and maintaining neuronal cells
04/20/1995WO1995010606A1 Deoxyribonucleic acids containing inactivated hormone responsive elements
04/20/1995WO1995010539A1 Growth differentiation factor-10
04/20/1995WO1995010305A1 Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes
04/20/1995WO1995010273A1 Use of protein kinase c activators for the manufacture of a medicament for killing hypoxic tumor cells
04/20/1995WO1995010265A1 Therapeutic delivery compositions and methods of use thereof
04/20/1995CA2174136A1 Tumor suppressor genes, proteins encoded thereby and use of said genes and proteins
04/20/1995CA2172271A1 Deoxyribonucleic acids containing inactivated hormone responsive elements
04/20/1995CA2171546A1 Growth differentiation factor-10
04/19/1995EP0648838A1 Tissue inhibitor of metalloproteinase type three (TIMP-3)
04/19/1995EP0648493A1 A method to reverse the phenotype of transformed cells by the transcription factor IRF-1
04/19/1995EP0648271A1 Adenovirus mediated transfer of genes to the gastrointestinal tract
04/19/1995EP0648269A1 Novel polypeptides having nmda receptor activity, nucleic acids encoding said polypeptides and applications
04/19/1995EP0648264A1 Bandage for continuous application of biologicals
04/19/1995EP0648261A1 A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and uses of said vector
04/19/1995EP0648128A1 DNA ENCODING PRECURSOR INTERLEUKIN 1$g(b) CONVERTING ENZYME
04/19/1995EP0648123A1 INHIBITORS OF PROTEIN TYROSINE-PHOSPHATASE -g(a) FOR TREATMENT OF TUMORS.
04/19/1995EP0517796B1 Oligonucleotide analogs
04/13/1995WO1995009918A1 Tissue inhibitor metalloproteinase type three (timp-3)
04/13/1995WO1995009916A1 Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases
1 ... 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 ... 870